Cargando…

2322. Reduced Vancomycin Susceptibility Among Pediatric Staphylococcus aureus Bloodstream Infections

BACKGROUND: Reduced vancomycin susceptibility (RVS) is considered to be present when the minimum inhibitory concentration (MIC) is equal to 2 µg/mL. RVS Staphylococcus aureus (SA) bloodstream infections (BSI) have been associated with worse outcomes than non-RVS BSI in adults but not been well studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ericson, Jessica, Canty, Ethan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253500/
http://dx.doi.org/10.1093/ofid/ofy210.1975
_version_ 1783373509434540032
author Ericson, Jessica
Canty, Ethan
author_facet Ericson, Jessica
Canty, Ethan
author_sort Ericson, Jessica
collection PubMed
description BACKGROUND: Reduced vancomycin susceptibility (RVS) is considered to be present when the minimum inhibitory concentration (MIC) is equal to 2 µg/mL. RVS Staphylococcus aureus (SA) bloodstream infections (BSI) have been associated with worse outcomes than non-RVS BSI in adults but not been well studied in children. METHODS: We reviewed the electronic medical records of infants and children admitted to Penn State Children’s Hospital with ≥1 blood culture positive for SA from 2005 to 2015. We abstracted demographic information, potential risk factors, laboratory results and clinical outcomes. We defined RVS as a vancomycin MIC = 2 µg/mL as determined by the clinical microbiology laboratory at the time of the infection. We used Chi square and Wilcoxon rank-sum tests to compare patient factors for RVS and non-RVS infections. Using a logistic regression adjusted for year and the presence of an infection-related complication, we calculated the odds of treatment failure for children with RVS and non-RVS BSI. For children with a central line in place at the time of the first positive culture, we also calculated the odds of treatment failure adjusted for year, presence of a complication and line removal. We defined treatment failure as death within 30 days of the first positive culture, recurrence of SA BSI within 30 days or a duration of bacteremia > 3 days. RESULTS: Of the 216 identified pediatric SA BSI, 139 (64%) had RVS: RVS was present in 63% of MSSA BSI and 65% of MRSA BSI, P = 0.835. There was no difference in age, sex, and racial distributions among children with RVS vs. non-RVS BSI. Similarly, hospitalization in the prior year, surgery within the prior 30 days, the presence of an underlying comorbidity or use of immunosuppressing medications were not more common for RVS vs. non-RVS BSI. RVS was not associated with an increased risk of treatment failure overall, odds ratio (OR)=1.34 (95% confidence interval: 0.71, 2.55), but did increase the odds of treatment failure if an indwelling central venous catheter was present and not removed, OR=3.14 (1.16, 8.54). CONCLUSION: RVS is common among pediatric SA BSI. For central line associated SA BSI, RVS was associated with increased odds of treatment failure compared with non-RVS infections if the line was retained. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6253500
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62535002018-11-28 2322. Reduced Vancomycin Susceptibility Among Pediatric Staphylococcus aureus Bloodstream Infections Ericson, Jessica Canty, Ethan Open Forum Infect Dis Abstracts BACKGROUND: Reduced vancomycin susceptibility (RVS) is considered to be present when the minimum inhibitory concentration (MIC) is equal to 2 µg/mL. RVS Staphylococcus aureus (SA) bloodstream infections (BSI) have been associated with worse outcomes than non-RVS BSI in adults but not been well studied in children. METHODS: We reviewed the electronic medical records of infants and children admitted to Penn State Children’s Hospital with ≥1 blood culture positive for SA from 2005 to 2015. We abstracted demographic information, potential risk factors, laboratory results and clinical outcomes. We defined RVS as a vancomycin MIC = 2 µg/mL as determined by the clinical microbiology laboratory at the time of the infection. We used Chi square and Wilcoxon rank-sum tests to compare patient factors for RVS and non-RVS infections. Using a logistic regression adjusted for year and the presence of an infection-related complication, we calculated the odds of treatment failure for children with RVS and non-RVS BSI. For children with a central line in place at the time of the first positive culture, we also calculated the odds of treatment failure adjusted for year, presence of a complication and line removal. We defined treatment failure as death within 30 days of the first positive culture, recurrence of SA BSI within 30 days or a duration of bacteremia > 3 days. RESULTS: Of the 216 identified pediatric SA BSI, 139 (64%) had RVS: RVS was present in 63% of MSSA BSI and 65% of MRSA BSI, P = 0.835. There was no difference in age, sex, and racial distributions among children with RVS vs. non-RVS BSI. Similarly, hospitalization in the prior year, surgery within the prior 30 days, the presence of an underlying comorbidity or use of immunosuppressing medications were not more common for RVS vs. non-RVS BSI. RVS was not associated with an increased risk of treatment failure overall, odds ratio (OR)=1.34 (95% confidence interval: 0.71, 2.55), but did increase the odds of treatment failure if an indwelling central venous catheter was present and not removed, OR=3.14 (1.16, 8.54). CONCLUSION: RVS is common among pediatric SA BSI. For central line associated SA BSI, RVS was associated with increased odds of treatment failure compared with non-RVS infections if the line was retained. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6253500/ http://dx.doi.org/10.1093/ofid/ofy210.1975 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Ericson, Jessica
Canty, Ethan
2322. Reduced Vancomycin Susceptibility Among Pediatric Staphylococcus aureus Bloodstream Infections
title 2322. Reduced Vancomycin Susceptibility Among Pediatric Staphylococcus aureus Bloodstream Infections
title_full 2322. Reduced Vancomycin Susceptibility Among Pediatric Staphylococcus aureus Bloodstream Infections
title_fullStr 2322. Reduced Vancomycin Susceptibility Among Pediatric Staphylococcus aureus Bloodstream Infections
title_full_unstemmed 2322. Reduced Vancomycin Susceptibility Among Pediatric Staphylococcus aureus Bloodstream Infections
title_short 2322. Reduced Vancomycin Susceptibility Among Pediatric Staphylococcus aureus Bloodstream Infections
title_sort 2322. reduced vancomycin susceptibility among pediatric staphylococcus aureus bloodstream infections
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253500/
http://dx.doi.org/10.1093/ofid/ofy210.1975
work_keys_str_mv AT ericsonjessica 2322reducedvancomycinsusceptibilityamongpediatricstaphylococcusaureusbloodstreaminfections
AT cantyethan 2322reducedvancomycinsusceptibilityamongpediatricstaphylococcusaureusbloodstreaminfections